Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human BAY2965501 study in advanced solid tumors
jRCT2031220737Phase 1Completed
- Sponsor
- Bayer
- Start
- Apr 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 1, open-label trial of veludacigib and pembrolizumab in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), gastric adenocarcinoma and 1 more (3 arms), sponsored by Bayer. Primary endpoints: Treatment-emergent adverse events and treatment-emergent serious adverse events, Dose-limiting toxicities and 7 more. Started Apr 2023; status: completed.
02
Drugs
veludacigibpembrolizumab
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2031220737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220737.